Sentence examples for benefiting or not from inspiring English sources

Evaluation of biomarkers is uniquely informative when performed in association with large randomized clinical trials, because this may allow the identification of specific subsets of patients as benefiting or not benefiting from a particular treatment.

The correct selection of patients that could benefit or not from TTM or TH-implementations seems critical in this heterogeneous group, as well as the underlying co-morbidities and severity of the post-resuscitation syndrome [74].

Kazi Tanvir et al. (2007) accessed whether the participants were benefited or not as result of intervention of the microcredit project among 330 recipients in Bangladesh under the agriculture diversification and intensification project.

The objective of the numerical simulations is to analyze how a shift in the technological frontier affects the retirement decision of workers depending on whether they have benefitted or not from a training process allowing to update their skills.

For example, it is impossible to predict which patients will benefit or not benefit from systemic first-line platinum/taxane-based chemotherapy.

Personal valence (four questions): refers to employees' perception of the degree they will potentially benefit (or not) prospective change should it be implemented.

C-statistics were used to compare the ability of the S-TPI to discriminate between patients that would benefit or not from thrombolytic treatment.

The correct selection of patients that could benefit or not from TTM or TH-implementations seems critical in this heterogeneous group, as well as the underlying co-morbidities and severity of the post-resuscitation syndrome [ 74].

However, taxanes are associated with toxic side-effects and, thus, identification of which patients benefit (or not) from the addition of this class of drugs is an unmet medical need.

Preoperative chemotherapy administered to breast cancer patients is the best model to identify baseline features able to predict which patients may be most likely to benefit or not from cytotoxic treatment (Bonadonna et al, 1998; Mamounas and Fisher, 2001).

In summary, where the study design permits the generation of meaningful data, most stakeholders other than participants will either benefit or not be adversely affected from the additional information.